ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2016 Financial Results

WALTHAM, Mass.--()--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, January 29, 2016, to discuss ImmunoGen's financial results for the three-month period ended December 31, 2015. Management also will provide an update on the Company.

To access the live call by phone, dial 913-312-0836; the conference ID is 5851737. The call also may be accessed through the Investors section of the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through February 12, 2016.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen’s ADC technology to develop novel anticancer therapies; it is used in Roche’s marketed product, Kadcyla®. More information about the Company can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

Contacts

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com

Recent Stories

RSS feed for ImmunoGen, Inc.

ImmunoGen, Inc.